Galderma, the world’s largest independent dermatology company, and Sofregen Medical, Inc., a medical device company pioneering the use of silk protein for tissue building and regeneration, announced they have signed a co-development and option-to-acquire agreement.

This collaboration will further expand Galderma’s capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers. The novel platform harnesses the unique power of silk protein to enable immediate volume restoration and provide structure that facilitates new tissue generation.

“At Galderma, we’re committed to advancing dermatology through constant innovation and joining forces with other industry pioneers. Combining Galderma’s capabilities and scale with Sofregen’s novel silk platform represents a watershed moment for the aesthetics market through the development of a new category of biostimulator fillers designed to make an impact for healthcare professionals and their patients,” said Galderma Global Head of Research and Development Baldo Scassellati Sforzolini.

Sofregen’s pioneering silk technology combines silk protein with an HA carrier. Naturally derived, silk has been shown to have unique properties for tissue support and regeneration, making it particularly well suited for facial aesthetic procedures.

Read more at Business Wire >>